NEW YORK ( TheStreet) -- CHANGE IN RATINGS
American Eagle Outfitters (AEO) downgraded at Brean Murray from Hold to Sell. $10 price target. Inventory remains high, ahead of back-to-school season.
Accretive Health (AH) initiated at JP Morgan with an Overweight rating and $27 price target. 2010 EPS estimates of 22 cents.
Accretive Health (AH) initiated at Credit Suisse with an Outperform rating and $17 price target. The company is well-positioned to benefit from the positive long-term trends in the revenue cycle industry, Credit Suisse said.Accretive Health (AH) was initiated with a Neutral rating at Robert Baird. $15 price target. Akamai Technologies (AKAM) downgraded from Buy to Neutral at Merriman, Curhan Ford. Valuation call, as the stock is up 80% year-to-date. Ameriprise Financial (AMP) was upgraded from Hold to Buy at Citigroup. $50 price target. Estimates also boosted, as the company should be able to successfully integrate the Columbia acquisition. AthenaHealth (ATHN) initiated at JP Morgan with a Neutral rating and $34 price target. 2010 EPS estimates of 49 cents. Bristol-Myers (BMY) was initiated with a Hold rating at Soleil Securities. $28 price target. Company has a promising pipeline, but already trades at a premium valuation. Berkshire Hathaway (BRK.B) was initiated with a Buy rating at Goldman Sachs. Intrinsic value of the stock is up around $101, and the company is leveraged to a cyclical economic recovery. Covidien (COV) was downgraded from Buy to Neutral at Goldman Sachs. $48 price target. Estimates also cut, as merger-and-acquisition dilution and currency should weigh on earnings. Walt Disney (DIS) was upgraded to Buy at Goldman Sachs. $42 price target. Company has a strong film slate and parks pricing appears to be recovering. Genworth Financial (GNW) was upgraded from Equal-weight to Overweight at Morgan Stanley. $20 price target. Improving mortgage insurance results should help drive growth. KBR (KBR) was initiated with a Buy rating at Sterne Agee. $28 price target. Company could see a higher multiple, with backlog quality improving. Eli Lilly (LLY) was initiated with a Sell rating at Soleil Securities. $28 price target. Company will have several products coming off patent soon. MedAssets (MDAS) was initiated with a neutral rating and $32 price target at JP Morgan. 2010 EPS estimates of 91 cents.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV